Loading…

A Ubiquitination Cascade Regulating the Integrated Stress Response and Survival in Carcinomas

Systematic identification of signaling pathways required for the fitness of cancer cells will facilitate the development of new cancer therapies. We used gene essentiality measurements in 1,086 cancer cell lines to identify selective coessentiality modules and found that a ubiquitin ligase complex c...

Full description

Saved in:
Bibliographic Details
Published in:Cancer discovery 2023-03, Vol.13 (3), p.766-795
Main Authors: Cervia, Lisa D, Shibue, Tsukasa, Borah, Ashir A, Gaeta, Benjamin, He, Linh, Leung, Lisa, Li, Naomi, Moyer, Sydney M, Shim, Brian H, Dumont, Nancy, Gonzalez, Alfredo, Bick, Nolan R, Kazachkova, Mariya, Dempster, Joshua M, Krill-Burger, John Michael, Piccioni, Federica, Udeshi, Namrata D, Olive, Meagan E, Carr, Steven A, Root, David E, McFarland, James M, Vazquez, Francisca, Hahn, William C
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Systematic identification of signaling pathways required for the fitness of cancer cells will facilitate the development of new cancer therapies. We used gene essentiality measurements in 1,086 cancer cell lines to identify selective coessentiality modules and found that a ubiquitin ligase complex composed of UBA6, BIRC6, KCMF1, and UBR4 is required for the survival of a subset of epithelial tumors that exhibit a high degree of aneuploidy. Suppressing BIRC6 in cell lines that are dependent on this complex led to a substantial reduction in cell fitness in vitro and potent tumor regression in vivo. Mechanistically, BIRC6 suppression resulted in selective activation of the integrated stress response (ISR) by stabilization of the heme-regulated inhibitor, a direct ubiquitination target of the UBA6/BIRC6/KCMF1/UBR4 complex. These observations uncover a novel ubiquitination cascade that regulates ISR and highlight the potential of ISR activation as a new therapeutic strategy. We describe the identification of a heretofore unrecognized ubiquitin ligase complex that prevents the aberrant activation of the ISR in a subset of cancer cells. This provides a novel insight on the regulation of ISR and exposes a therapeutic opportunity to selectively eliminate these cancer cells. See related commentary Leli and Koumenis, p. 535. This article is highlighted in the In This Issue feature, p. 517.
ISSN:2159-8274
2159-8290
DOI:10.1158/2159-8290.CD-22-1230